Management of Chronic Liver Disease

Introduction to Chronic Liver Disease Management

The American Association for the Study of Liver Diseases recommends identifying and treating the specific underlying cause of chronic liver disease to prevent progression to cirrhosis and hepatocellular carcinoma 1

The American Association for the Study of Liver Diseases recommends using first-line agents entecavir 0.5 mg daily, tenofovir disoproxil fumarate 300 mg daily, or peginterferon alfa-2a in patients with elevated ALT and HBV DNA ≥2000 IU/mL 1
The American Association for the Study of Liver Diseases recommends that all cirrhotic patients with detectable HBV DNA require treatment regardless of ALT levels 1
The American Association for the Study of Liver Diseases recommends sustained viral suppression to prevent cirrhosis progression and reduce HCC risk—lifelong surveillance remains mandatory 1
The American Association for the Study of Liver Diseases recommends using direct-acting antivirals (DAAs) to achieve sustained viral response in all eligible patients with chronic hepatitis C 1

The American Association for the Study of Liver Diseases recommends lifestyle modification as the primary treatment, with 7-10% weight loss required to improve steatohepatitis and achieve fibrosis regression 1
The American Association for the Study of Liver Diseases recommends creating a 500-1000 kcal/day deficit: typically 1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men 1
The American Association for the Study of Liver Diseases recommends weight loss must be gradual at 500-1000g per week maximum—rapid weight loss worsens liver disease 1
The American Association for the Study of Liver Diseases recommends implementing a Mediterranean diet pattern with daily vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil—this reduces liver fat even without weight loss 1
The American Association for the Study of Liver Diseases recommends prescribing 150-300 minutes of moderate-intensity aerobic exercise per week or 75-150 minutes of vigorous-intensity exercise 1

The American Association for the Study of Liver Diseases recommends identifying and correcting precipitating factors first—this resolves up to 90% of cases 2
The European Association for the Study of the Liver recommends lactulose as first-line treatment, titrated to achieve 2-3 soft stools per day 3, 2
The American Association for the Study of Liver Diseases recommends rifaximin as second-line or additional therapy for patients with recurrent episodes despite lactulose use 2
The American Association for the Study of Liver Diseases recommends secondary prophylaxis with lactulose after the first episode of overt hepatic encephalopathy 2

The American Association for the Study of Liver Diseases recommends using a stepwise approach with FIB-4 score followed by transient elastography to identify patients with advanced fibrosis who require closer monitoring 1
The American Association for the Study of Liver Diseases recommends performing 6-monthly ultrasound and AFP measurement for all cirrhotic patients 1
The American Association for the Study of Liver Diseases recommends lifelong HCC surveillance for cirrhotic patients, even after viral clearance 1

The American Association for the Study of Liver Diseases recommends using statins for dyslipidemia in all NAFLD patients—they carry no increased risk of serious liver injury and reduce HCC risk by 37% 1

The European Association for the Study of the Liver recommends bone densitometry evaluation in patients with previous fragility fractures, those treated with corticosteroids, and before liver transplantation 5
The European Association for the Study of the Liver recommends providing supplements of calcium (1,000–1,500 mg/d) and 25-hydroxy-vitamin D (400–800 IU/d or 260 μg every 2 weeks) 5

The American Association for the Study of Liver Diseases recommends vaccinating against hepatitis B: all infants (universal childhood immunization), high-risk adults, and exposed individuals 1
The American Association for the Study of Liver Diseases recommends vaccinating against hepatitis A: all anti-HAV negative patients with chronic liver disease 1

The American Association for the Study of Liver Diseases recommends not relying exclusively on ammonia levels for diagnosis of hepatic encephalopathy—they do not provide diagnostic, prognostic, or staging value 2
The American Association for the Study of Liver Diseases recommends not failing to seek precipitating factors in hepatic encephalopathy, which cause 90% of cases 2
The American Association for the Study of Liver Diseases recommends not using rapid weight loss strategies in MASLD—gradual weight loss at 500-1000g per week maximum is essential as rapid weight loss worsens liver disease 1
The American Association for the Study of Liver Diseases recommends not discontinuing HCC surveillance after achieving sustained viral response in cirrhotic patients—lifelong surveillance remains mandatory 1